Measurement of Arginase Activity in Sera of Iraqi Acromegaly Patients with Diabetes

Authors

  • Fatima Khazaal Malek Department of Chemistry, College of Science, Mustansiriyah University, 10052 Baghdad, IRAQ. https://orcid.org/0009-0009-9268-123X
  • Salma Abdul-Rudha Abbas Department of Chemistry, College of Science, Mustansiriyah University, 10052 Baghdad, IRAQ.
  • Baydaa Ahmed Abed National Diabetes Center, Mustansiriyah University, Baghdad, IRAQ. https://orcid.org/0000-0002-8895-7901

DOI:

https://doi.org/10.23851/mjs.v35i1.1362

Keywords:

Acromegaly, Growth Hormone, Insulin-Like Growth Factor-1, Arginase, Diabetes mellitus, Lipid profile

Abstract

The goal of this study was to measure arginase enzyme activity in diabetic acromegaly Iraqi patients and compare it to a control group. This study included 80 participants, whose ages ranged from 25 to 65, and was conducted on forty diabetic acromegaly Iraqi patients attending the national diabetes center of Mustansiriyah University in Baghdad and forty healthy individuals (as a control group). The results showed a highly significant reduction in arginase activity and High-density lipoprotein-cholesterol (HDL-C), Urea levels were reduced not significantly, whereas a highly significant increase in levels of Growth Hormone (GH), Insulin-Like Growth Factor-1 (IGF-1), Fasting Serum glucose (FSG), Total Cholesterol (TC), Triglycerides (TG), Low-density lipoprotein-cholesterol (LDL-C), and Very low-density lipoprotein-cholesterol (VLDL-C)) compared to control. A significant positive correlation was revealed between arginase activity and FSG levels in diabetic acromegaly patients. In conclusion, diabetic acromegaly patients had a significant decreased in serum arginase activity with no significant decrease urea levels, which indicates that their bodies store more nitrogen compounds to be utilized in constructing processes.

 

Downloads

Download data is not yet available.

References

F. Bandeira, A. L. P. Lemos, and S. R. de Lima Andrade, "Acromegaly BT - Endocrinology and Diabetes: A Problem Oriented Approach," F. Bandeira, H. Gharib, L. Griz, and M. Faria, Eds. Cham: Springer International Publishing, 2022, pp. 55-60.

CrossRef

"Acromegaly," Nat. Rev. Dis. Prim., vol. 5, no. 1, p. 21, 2019.

CrossRef | PubMed

S. Camerini et al., "Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management," J. Endocrinol. Invest., no. 0123456789, 2022.

CrossRef | PubMed

F. Langlois, G. M. Suarez, and M. Fleseriu, "Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly," F1000Research, vol. 9, p. 791, Jul. 2020.

CrossRef | PubMed

C. Badiu and P. Witek, "Editorial: Insights Into Acromegaly Complications," Front. Endocrinol. (Lausanne)., vol. 13, No. June, pp. 1-2, 2022, doi: 10.3389/fendo.2022.905145.

CrossRef | PubMed

N. Coronel-Restrepo, L. V. Syro, F. Rotondo, and K. Kovacs, "Anatomy of the Pituitary Gland," Pituit. Adenomas, pp. 1-19, 2022.

CrossRef

"Acromegaly Johns Hopkins Medicine.".

M. Bolanowski, M. Ruchała, W. Zgliczyński, B. Kos-Kudła, A. Hubalewska-Dydejczyk, and A. Lewiński, "Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology," Endokrynol. Pol., vol. 70, No. 1, pp. 2-18, 2019.

CrossRef | PubMed

D. P. Bray, S. Mannam, R. S. Rindler, J. W. Quillin, and N. M. Oyesiku, "Surgery for acromegaly: Indications and goals," Front. Endocrinol. (Lausanne)., vol. 13, No. August, pp. 1-12, 2022.

CrossRef | PubMed

M. Gierach and R. Junik, "Aberrations in carbohydrate metabolism in patients with diagnosed acromegaly - observational study," Endokrynol. Pol., pp. 743-744, 2022.

CrossRef

R. Sharma, J. Kopchick, V. Puri, V. Sharma, "Effect of growth hormone on insulin signaling," Mol. Cell. Endocrinol., vol. 518, p. 111038, 2020.

CrossRef | PubMed

N. C. Olarescu, K. Gunawardane, T. K. Hansen, N. Møller, and J. O. L. Jørgensen, "Normal Physiology of Growth Hormone in Adults," Endotext, Oct. 2019.

T. Yoshida and P. Delafontaine, "Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy," Cells, vol. 9, No. 9, p. 1970, Aug. 2020.

CrossRef | PubMed

J. Hinson, P. Raven, and S. Chew, "THE HYPOTHALAMUS AND PITUITARY PART II: THE ANTERIOR PITUITARY," Endocr. Syst., pp. 39-51, 2010.

CrossRef

I. Bentov and H. Werner, Insulin-like Growth Factor-1, Second Edi. Elsevier Inc., 2013.

CrossRef

J. I. Jones and D. R. Clemmons, "Insulin-like growth factors and their binding proteins: biological actions," Endocr. Rev., vol. 16, No. 1, pp. 3-34, 1995.

CrossRef | PubMed

N. AsghariHanjani and M. Vafa, "The role of IGF-1 in obesity, cardiovascular disease, and cancer," Med. J. Islam. Repub. Iran, vol. 33, No. 1, pp. 1-4, 2019.

CrossRef | PubMed

D. R. Clemmons, "Metabolic Actions of IGF-I in Normal Physiology and Diabetes," Endocrinol. Metab. Clin. North Am., vol. 41, No. 2, p. 425, Jun. 2012.

CrossRef | PubMed

A. M. Hannon, C. J. Thompson, and M. Sherlock, "Diabetes in Patients with Acromegaly," Curr. Diab. Rep., vol. 17, No. 2, Feb. 2017.

CrossRef | PubMed

M. Mercado and C. Ramírez-Rentería, "Metabolic Complications of Acromegaly," in Frontiers of Hormone Research, vol. 49, 2017, pp. 20-28.

CrossRef | PubMed

B. Abed, S. Al-AAraji, and I. Salman, "Estimation of Galanin hormone in patients with newly thyroid dysfunction in type 2 diabetes mellitus," Biochem. Cell. Arch, vol. 21, No. 1, pp. 1317-1321, 2021.

CrossRef

H. S. Ahmed, "Serum Leptin as a Biomarker in Diabetes BT - Biomarkers in Diabetes," V. B. Patel and V. R. Preedy, Eds. Cham: Springer International Publishing, 2022, pp. 1-16.

CrossRef

T. Brue et al., "Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy," Endocrine, vol. 63, No. 3, pp. 563-572, Mar. 2019.

CrossRef | PubMed

G. Vila, J. O. L. Jørgensen, A. Luger, and G. K. Stalla, "Insulin resistance in patients with acromegaly," Front. Endocrinol. (Lausanne)., vol. 10, p. 509, 2019.

CrossRef | PubMed

F. Niu et al., "Arginase: An emerging and promising therapeutic target for cancer treatment," Biomed. Pharmacother., vol. 149, p. 112840, 2022.

CrossRef | PubMed

A. A. Al-Anbari, A. H. Alta'ee, and S. F. Al-Saad, "A study of arginase-1 activity and lipid profile in patients with myocardial infarction," J. Adv. Biotechnol. Exp. Ther., vol. 5, No. 3, pp. 553-561, 2022.

CrossRef

G. S. Clemente, A. van Waarde, I. F. Antunes, A. Dömling, and P. H. Elsinga, "Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective," Int. J. Mol. Sci., vol. 21, No. 15, p. 5291, Jul. 2020.

CrossRef | PubMed

S. jumah Abdand, S. A. Abbas, and B. A. Abed, "Study of arginase activity in serum of patients with hypothyroidism and type 2 diabetes mellitus," Int. J. Health Sci. (Qassim)., vol. 6, No. June, pp. 4809-4816, Jun. 2022.

CrossRef

Z. Porembska and M. Kedra, "Early diagnosis of myocardial infarction by arginase activity determination," Clin. Chim. Acta, vol. 60, No. 3, pp. 355-361, May 1975.

CrossRef | PubMed

A. H. Abdullah, I. K. Mohaisn, A. S. Nsaif, and A. H. M. Safaryan, "Studying the impact of vitamin D deficiency in Iraqi acromegalic patients and its relation with some biochemical parameters," Ann. Trop. Med. Public Heal., vol. 23, No. 11, 2020.

CrossRef

M. C. Vázquezâ€borrego, M. Del Rioâ€Moreno, and R. D. Kineman, "Towards Understanding the Direct and Indirect Actions of Growth Hormone in Controlling Hepatocyte Carbohydrate and Lipid Metabolism," Cells 2021, vol. 10, No. 10, p. 2532, Sep. 2021.

CrossRef | PubMed

"Pediatric Implications of Normal Insulin-GH-IGF-Axis Physiology - PubMed.

H. A. K. Hussain, N. Q. Muftin, M. N. Al-jibouri, and G. Ben Salah, "Study of the Arginase Activity and Other Biochemical Parameters in Patients with Coronary Artery Disease in Baghdad Governorate-Iraq," Al-Mustansiriyah J. Sci., vol. 34, No. 1 SE-Chemical Science, pp. 37-44, Mar. 2023.

CrossRef

A. S. Hameed, F. M. Khaleel, and A. M. Rahma, "The Response of Acromegalic patients (Diabetic versus non-diabetic) to Long-acting-repeatable Octreotide (LAR) in the presence or absence of Glutathion S transferase (GSTM1, GSTT1) Genes," J. Pharm. Sci. Res., vol. 10, No. 12, p. 3090, 2018.

A. Hameed, F. Khaleel, and A. Rahma, "The response of acromegalic patients (Diabetic versus non- diabetic) to Long -acting -repeatable Octreotide (LAR) in the presence or absence of Glutathion S transferase (GSTM1,GSTT1) Genes," Jan. 2023.

A. Shawkat and H. Majeed, "Assessment the Apelin , Glutathione S-transferase Polymorphism and some of Biochemical Parameters in Acromegaly Patients," 2019.

A. R. Mahmood, M. R. Abdullah, and K. T. Abdullah, "Determination of Some Biochemical Parameters of Acromegalic Patients with Type 2 Diabetes Mellitus," J. Pharm. Sci. Res., vol. 11, no. 3, pp. 787-790, 2019.

N. Moller et al., "Growth hormone and protein metabolism," Clin. Nutr., vol. 28, No. 6, pp. 597-603, Dec. 2009.

CrossRef | PubMed

G. J. Hamwi, T. G. Skillman, and K. C. Tufts, "Acromegaly," Am. J. Med., vol.29, No. 4, pp. 690-699, Oct. 1960

CrossRef | PubMed

Downloads

Key Dates

Received

13-04-2023

Revised

03-05-2023

Accepted

12-05-2023

Published

30-03-2024

Issue

Section

Original Article

How to Cite

[1]
F. K. Malek, S. A.-R. . Abbas, and B. A. Abed, “Measurement of Arginase Activity in Sera of Iraqi Acromegaly Patients with Diabetes”, Al-Mustansiriyah J. Sci., vol. 35, no. 1, pp. 44–49, Mar. 2024, doi: 10.23851/mjs.v35i1.1362.

Similar Articles

1-10 of 234

You may also start an advanced similarity search for this article.